Can a new tracer light up hidden prostate cancer?

NCT ID NCT07765940

Not yet recruiting Diagnosis Sponsor: RadAlliance Therapeutics, Inc Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial is testing an experimental imaging agent called [⁶⁴Cu]Cu-RAX301, which is designed to bind to prostate cancer cells and show up on PET/CT scans. The study includes men with prostate cancer who are either about to have surgery to remove the prostate or who may have a recurrence of the disease. The goal is to see if the agent is safe and can accurately detect cancer and its spread, which could improve how prostate cancer is diagnosed and monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental PET imaging agent called [⁶⁴Cu]Cu-RAX301, given as a single injection
What this could lead to: If successful, this could provide a more accurate imaging method to detect prostate cancer and find where it has returned, helping guide treatment decisions.
What could go wrong: This is an early-phase study with a small number of participants, so the imaging agent may not prove accurate enough or may have safety issues. Results will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.